Euro-Med Laboratories Phil., Inc. (PSE:EURO)
Philippines
· Delayed Price · Currency is PHP 0.9000
0.00 (0.00%)
Last updated: Jun 4, 2025
PSE:EURO Income Statement
Financials in millions PHP. Fiscal year is January - December.
Millions PHP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 6,257 | 5,796 | 5,264 | 4,224 | 3,587 | 3,829 | Upgrade
|
| Revenue Growth (YoY) | 17.87% | 10.11% | 24.62% | 17.75% | -6.31% | -32.68% | Upgrade
|
| Cost of Revenue | 4,115 | 3,785 | 3,370 | 2,731 | 2,150 | 2,213 | Upgrade
|
| Gross Profit | 2,142 | 2,012 | 1,894 | 1,493 | 1,438 | 1,617 | Upgrade
|
| Selling, General & Admin | 1,398 | 1,312 | 1,209 | 1,025 | 991.39 | 1,045 | Upgrade
|
| Other Operating Expenses | 32.76 | 30.58 | 32.75 | 28.03 | 35.23 | 31.06 | Upgrade
|
| Operating Expenses | 1,431 | 1,343 | 1,242 | 1,053 | 1,027 | 1,076 | Upgrade
|
| Operating Income | 711.24 | 669.03 | 652.58 | 440.44 | 411.1 | 540.72 | Upgrade
|
| Interest Expense | -310.89 | -307.78 | -270.45 | -206.8 | -213.19 | -215.36 | Upgrade
|
| Interest & Investment Income | 3.13 | 2.93 | 1.29 | 0.5 | 0.7 | 6.47 | Upgrade
|
| Currency Exchange Gain (Loss) | 13.67 | 13.34 | 1.66 | 34.36 | -16.98 | -37.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 31.34 | 37.48 | 0.09 | 12.88 | 5.85 | 6.86 | Upgrade
|
| EBT Excluding Unusual Items | 448.48 | 414.99 | 385.17 | 281.39 | 187.48 | 301.38 | Upgrade
|
| Gain (Loss) on Sale of Investments | 22.47 | 22.47 | 13.23 | -1.09 | 43.93 | 3.65 | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.79 | - | - | - | - | - | Upgrade
|
| Pretax Income | 468.15 | 437.46 | 398.4 | 280.3 | 231.41 | 305.03 | Upgrade
|
| Income Tax Expense | 108.08 | 99.78 | 108.45 | 80.41 | 62.36 | 94.98 | Upgrade
|
| Net Income | 360.07 | 337.68 | 289.95 | 199.89 | 169.05 | 210.05 | Upgrade
|
| Net Income to Common | 360.07 | 337.68 | 289.95 | 199.89 | 169.05 | 210.05 | Upgrade
|
| Net Income Growth | 21.95% | 16.46% | 45.05% | 18.25% | -19.52% | -45.98% | Upgrade
|
| Shares Outstanding (Basic) | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 | Upgrade
|
| Shares Outstanding (Diluted) | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 | Upgrade
|
| EPS (Basic) | 0.09 | 0.08 | 0.07 | 0.05 | 0.04 | 0.05 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.08 | 0.07 | 0.05 | 0.04 | 0.05 | Upgrade
|
| EPS Growth | 24.19% | 13.46% | 45.05% | 21.52% | -20.00% | -47.13% | Upgrade
|
| Free Cash Flow | 76.51 | 50.73 | 62.26 | 59.35 | 202.83 | -9.9 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | 0.01 | 0.01 | 0.01 | 0.05 | -0.00 | Upgrade
|
| Dividend Per Share | - | - | 0.060 | 0.035 | 0.020 | 0.015 | Upgrade
|
| Dividend Growth | - | - | 71.43% | 75.00% | 33.33% | -70.00% | Upgrade
|
| Gross Margin | 34.24% | 34.71% | 35.98% | 35.35% | 40.08% | 42.22% | Upgrade
|
| Operating Margin | 11.37% | 11.54% | 12.40% | 10.43% | 11.46% | 14.12% | Upgrade
|
| Profit Margin | 5.75% | 5.83% | 5.51% | 4.73% | 4.71% | 5.49% | Upgrade
|
| Free Cash Flow Margin | 1.22% | 0.88% | 1.18% | 1.41% | 5.65% | -0.26% | Upgrade
|
| EBITDA | 985.45 | 928.42 | 890.72 | 664.09 | 639 | 762.97 | Upgrade
|
| EBITDA Margin | 15.75% | 16.02% | 16.92% | 15.72% | 17.81% | 19.93% | Upgrade
|
| D&A For EBITDA | 274.22 | 259.39 | 238.14 | 223.65 | 227.9 | 222.25 | Upgrade
|
| EBIT | 711.24 | 669.03 | 652.58 | 440.44 | 411.1 | 540.72 | Upgrade
|
| EBIT Margin | 11.37% | 11.54% | 12.40% | 10.43% | 11.46% | 14.12% | Upgrade
|
| Effective Tax Rate | 23.09% | 22.81% | 27.22% | 28.69% | 26.95% | 31.14% | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.